Document Classification

Section Type: RESULTS

Text: After 48 weeks of omalizumab, reductions in protocol-defined exacerbations were greater in high versus low subgroups for all three biomarkers : FE (NO), 53 % (95 % confidence interval [CI], 37-70 ; P = 0. 001) versus 16 % (95 % CI, -32 to 46 ; P = 0. 45) ; eosinophils, 32 % (95 % CI, 11-48 ; P = 0. 005) versus 9 % (95 % CI, -24 to 34 ; P = 0. 54) ; and periostin, 30 % (95 % CI, -2 to 51 ; P = 0. 07) versus 3 % (95 % CI, -43 to 32 ; P = 0. 94).